Dermatology Denial Appeal Automation: Accelerating Revenue Recovery

The Persistent Challenge of Dermatology Denials

Dermatology practices frequently encounter prior authorization denials, particularly for high-cost biologics used in psoriasis, atopic dermatitis, and hidradenitis suppurativa, as well as for Mohs micrographic surgery. Common denial reasons, such as unfulfilled step therapy requirements, lack of documented disease severity (e.g., PASI, EASI scores), or Mohs Appropriate Use Criteria (AUC) mismatches, necessitate complex and time-consuming appeal processes. These manual workflows divert clinical staff from patient care and directly impact revenue.

High-Volume PA Triggers and Common Denial Reasons in Dermatology

• Biologics for psoriasis and psoriatic arthritis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi), often denied for unfulfilled step therapy.
• Biologics for atopic dermatitis (e.g., Dupixent, Adbry), frequently denied due to insufficient severity documentation or age-specific criteria.
• Hidradenitis suppurativa biologics (e.g., Humira), requiring specific diagnostic and prior treatment documentation.
• Mohs micrographic surgery, where denials commonly arise from site/tumor type mismatches against payer-adopted AUC.
• Advanced skin cancer treatments (e.g., immunotherapy for melanoma), requiring detailed staging and prior treatment history.
• Phototherapy, particularly home-based, which may be denied if prior topical therapy trials are not clearly documented.

Klivira's Automated Appeal Workflow Tailored for Dermatology

Klivira's platform streamlines the entire denial appeal process, specifically addressing the unique complexities of dermatology. By leveraging intelligent classification of CARC/RARC codes and a deep understanding of AAD Clinical Guidelines and NCCN frameworks, our system automates the critical steps from denial receipt to resubmission. This ensures that dermatology-specific denial reasons, such as missing PASI/EASI scores or Mohs AUC discrepancies, are precisely addressed with relevant clinical evidence.

Core Components of Klivira's Dermatology Denial Appeal Automation

• Intelligent denial classification: Utilizes normalized CARC/RARC taxonomy to identify specific dermatology denial reasons (e.g., step therapy failure, Mohs AUC mismatch).
• Automated appeal letter generation: Composes payer-specific appeal letters, pre-populating with patient clinical data and referencing relevant AAD/NCCN guidelines for conditions like psoriasis or melanoma.
• FHIR-based clinical evidence extraction: Automatically pulls required documentation from EMRs, such as PASI/EASI/BSA scores, prior topical/systemic therapy trials, and pre-biologic screening results (TB, hepatitis).
• Payer-policy-aware appeal pathway selection: Ensures the correct appeal level and timely-filing windows are met, adapting to payer-specific rules for dermatology services and drugs.
• Peer-to-peer scheduling support: Facilitates scheduling and provides clinicians with comprehensive denial context and patient history for clinical-necessity appeals involving biologics or complex procedures.
• Real-time status tracking and outcome capture: Monitors appeal progress with timely-filing enforcement and escalations, writing back appeal outcomes to the EMR for billing and analytics.

Seamless EMR and Payer Integration for Dermatology Practices

Klivira integrates directly with major EMR systems via SMART on FHIR, enabling automated extraction of dermatology-specific clinical notes, lab results, and medication histories crucial for appeals. Our platform connects with payer portals, X12 278 gateways, and Da Vinci PAS-conformant channels to submit appeal packets efficiently. This robust integration ensures that documentation for biologics (medical vs. pharmacy benefit), Mohs surgery, and other specialty treatments is exchanged securely and accurately, minimizing manual data entry and reducing re-work.

Optimizing Revenue Cycle and Enhancing Patient Access in Dermatology

By automating dermatology denial appeal workflows, Klivira significantly reduces the administrative burden and rework costs associated with managing denials, as highlighted by industry benchmarks like the CAQH Index. Faster appeal resolution for high-value biologics and Mohs procedures means quicker revenue recovery and improved cash flow for practices. More importantly, it ensures that patients with chronic conditions like psoriasis, atopic dermatitis, or skin cancer receive timely access to the therapies and procedures they need, enhancing overall patient care and satisfaction.